 |
 |
    |
|||
 The CompanyAdvisory BoardRecent NewsLinksContact Us
|
The
Company BioGenesis Investment Group, LLC was originally formed to purchase technology and technology options and to develop these technologies through early development stages. Recently, BioGenesis Investment Group assisted with the transfer of a technology license from Mayo Clinic to Corus Pharma in Seattle, Washington. In 2001, BioGenesis Investment Group developed a technology valuation model for the biotech industry, which took into account the unique valuation nature of drugs in their development phase. Upon making this model public with the Nature Biotechnology Magazine article last September, the Red Herring Magazine article in March, 2002, and the various newspaper articles over the past few months, we received an overwhelming response from the Life Sciences and Finance industries. The company has received significant recognition for its ability to value biotechnologies using its valuation model and for structuring biotech investment and equity programs. We have presented papers to Tech Transfer and Biotechnology industry conferences here and in Europe. Universities and companies from around America have called, with great interest in our new development in biotech valuations. This valuation technique, combined with a financial services business and revenue model, meets a critical need in the biotech industry for:
We have developed relationships with our strategic partners, all of whom have endorsed our new financial services concept and who are working with us to develop the biotech investment banking industry. We are the first mover in the industry and believe we provide a great investment opportunity.
|
||||